(Total Views: 871)
Posted On: 07/07/2017 6:35:03 PM
Post# of 1460
Below good posts copied from IHUB AVXL board,
Fletch
falconer66a Friday, 07/07/17 09:09:36 AM
Re: Penny Double post# 110464
Post # 110467of 110516 Go
Anavex 3-71 Will Be Big
With upcoming clinical trials of Rett Syndrome and Alzheimer’s, the focus, quite properly, has been on the drug being tested, Anavex 2-73. The Anavex 2-73 data from murine (rat and mouse) experimentation has been thoroughly laid out in technical papers. The human data from the Australian trial, depicted at the CTAD conference presentation, is astounding, showing maintenance or improvement of cognition for mid- to moderate-level Alzheimer’s patients, without disqualifying side effects. Not a scintilla of evidence that this won’t be exhaustively confirmed in the much larger Anavex 2-73 Phase 3 trial to be started later this year.
But the Anavex pipeline is massive. Presently, only Anavex 2-73 has had any human trials. But, as the link in the reference post shoes, Anavex 3-71 may be even more efficacious.
Quote:
“... although that the transgenic McGill rats had a very late stage of Alzheimer’s disease-like pathology (13 months of age), treatment with ANAVEX 3-71 fully reversed cognitive deficits, reduced amyloid pathology and also significantly reduced inflammation. Furthermore, the sustained recovery in cognition and pathophysiology observed following a month-long washout phase in advanced pathology (19 months of age) strongly suggests true disease-modifying properties of ANAVEX 3-71.”
The Anavex bench is strong and deep. Anavex 3-71 likely to be even more powerful than 2-73 for any number of central nervous system conditions.
Another post below.........................
Biology, Chart-reading, or the Failures of Others?
I lost a bit in an earlier company, which had, likewise, a transformative biotech, but was under-funded and unable to bring its molecules to FDA approval. I had the good sense (did due diligence) to limit my initial position, should the company (as it happened) not be able to synthesize, test, and get approved its unique antibiotic molecules.
Anavex skeptics from the start have boldly (and accurately) proclaimed the exceptionally low success rate of start-up biotechs, conveniently lumping Anavex with them. Seen one, seen ‘em all, is the implication.
This is a particular problem with Anavex, inasmuch as it’s targeting Alzheimer’s disease. Any number of Big Pharmaceuticals have spent billions of dollars on a multitude of drugs aimed at clearing amyloid beta and tau tangle protein wastes in nerves. Not a one of these have been successful.
Therefore, without any useful understanding of molecular biology and neuron cytology, one can necessarily presume that Anavex can be no different. Simply put, after three or more decades of drug trials against Alzheimer’s nothing has ever worked. It’s good thinkingand due diligence on the part of retail equity investors, then, to be assured Anavex can be no different. End of game. Time to go on to something else.
My decision in taking (presently) a small Anavex position is NOT based upon chart-reading, nor the multiple failures of other drug companies. I’m a biologist and understand elemental neuron cytology, physiology, and all of the associated molecular biology. With this, it is clear Anavex 2-73 operates in no manner similar to the protein waste-clearing drugs that have all failed.
And, as a biologist, I know (as does FDA) the critical and confirming accuracies of murine studies for pre-clinical testing and characterizations of new drugs. The nerves and cellular chemistry of rats are virtually identical to humans.
Moreover, the specific mechanisms of action of Anavex 2-73, on a molecular and sub-cellular level have been clearly discerned and presented by Anavex scientists (see my earlier posts on this).
And, unlike my previous biotech (which failed), Anavex is strongly funded, able to go forward with the ensuing clinical trials.
I would encourage retail investors to closely examine and consider both due-diligence perspectives:
1. The record of previous drug trials by many companies against Alzheimer’s (all of which have failed).
and/or
2. The scientific determination that the Anavex approach to Alzheimer’s treatment is categorically very different from the previous failures, because of Anavex 2-73's unique, effective, safe mechanisms of action in restoring neuron and nerve homeostasis.
Fletch
falconer66a Friday, 07/07/17 09:09:36 AM
Re: Penny Double post# 110464
Post # 110467of 110516 Go
Anavex 3-71 Will Be Big
With upcoming clinical trials of Rett Syndrome and Alzheimer’s, the focus, quite properly, has been on the drug being tested, Anavex 2-73. The Anavex 2-73 data from murine (rat and mouse) experimentation has been thoroughly laid out in technical papers. The human data from the Australian trial, depicted at the CTAD conference presentation, is astounding, showing maintenance or improvement of cognition for mid- to moderate-level Alzheimer’s patients, without disqualifying side effects. Not a scintilla of evidence that this won’t be exhaustively confirmed in the much larger Anavex 2-73 Phase 3 trial to be started later this year.
But the Anavex pipeline is massive. Presently, only Anavex 2-73 has had any human trials. But, as the link in the reference post shoes, Anavex 3-71 may be even more efficacious.
Quote:
“... although that the transgenic McGill rats had a very late stage of Alzheimer’s disease-like pathology (13 months of age), treatment with ANAVEX 3-71 fully reversed cognitive deficits, reduced amyloid pathology and also significantly reduced inflammation. Furthermore, the sustained recovery in cognition and pathophysiology observed following a month-long washout phase in advanced pathology (19 months of age) strongly suggests true disease-modifying properties of ANAVEX 3-71.”
The Anavex bench is strong and deep. Anavex 3-71 likely to be even more powerful than 2-73 for any number of central nervous system conditions.
Another post below.........................
Biology, Chart-reading, or the Failures of Others?
I lost a bit in an earlier company, which had, likewise, a transformative biotech, but was under-funded and unable to bring its molecules to FDA approval. I had the good sense (did due diligence) to limit my initial position, should the company (as it happened) not be able to synthesize, test, and get approved its unique antibiotic molecules.
Anavex skeptics from the start have boldly (and accurately) proclaimed the exceptionally low success rate of start-up biotechs, conveniently lumping Anavex with them. Seen one, seen ‘em all, is the implication.
This is a particular problem with Anavex, inasmuch as it’s targeting Alzheimer’s disease. Any number of Big Pharmaceuticals have spent billions of dollars on a multitude of drugs aimed at clearing amyloid beta and tau tangle protein wastes in nerves. Not a one of these have been successful.
Therefore, without any useful understanding of molecular biology and neuron cytology, one can necessarily presume that Anavex can be no different. Simply put, after three or more decades of drug trials against Alzheimer’s nothing has ever worked. It’s good thinkingand due diligence on the part of retail equity investors, then, to be assured Anavex can be no different. End of game. Time to go on to something else.
My decision in taking (presently) a small Anavex position is NOT based upon chart-reading, nor the multiple failures of other drug companies. I’m a biologist and understand elemental neuron cytology, physiology, and all of the associated molecular biology. With this, it is clear Anavex 2-73 operates in no manner similar to the protein waste-clearing drugs that have all failed.
And, as a biologist, I know (as does FDA) the critical and confirming accuracies of murine studies for pre-clinical testing and characterizations of new drugs. The nerves and cellular chemistry of rats are virtually identical to humans.
Moreover, the specific mechanisms of action of Anavex 2-73, on a molecular and sub-cellular level have been clearly discerned and presented by Anavex scientists (see my earlier posts on this).
And, unlike my previous biotech (which failed), Anavex is strongly funded, able to go forward with the ensuing clinical trials.
I would encourage retail investors to closely examine and consider both due-diligence perspectives:
1. The record of previous drug trials by many companies against Alzheimer’s (all of which have failed).
and/or
2. The scientific determination that the Anavex approach to Alzheimer’s treatment is categorically very different from the previous failures, because of Anavex 2-73's unique, effective, safe mechanisms of action in restoring neuron and nerve homeostasis.
(0)
(0)Scroll down for more posts ▼
